title: Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination.
abstract: CD8+ T cells are important for clearance of neurotropic mouse hepatitis virus (MHV) strain A59, although their possible role in A59-induced demyelination is not well understood. We developed an adoptive-transfer model to more clearly elucidate the role of virus-specific CD8+ T cells during the acute and chronic phases of infection with A59 that is described as follows. C57BL/6 mice were infected with a recombinant A59 virus expressing the gp33 epitope, an H-2Db-restricted CD8+ T-cell epitope encoded in the glycoprotein of lymphocytic choriomeningitis virus, as a fusion with the enhanced green fluorescent protein (RA59-gfp/gp33). P14 splenocytes (transgenic for a T-cell receptor specific for the gp33 epitope) were transferred at different times pre- and postinfection (p.i.). Adoptive transfer of P14 splenocytes 1 day prior to infection with RA59-gfp/gp33, but not control virus lacking the gp33 epitope, RA59-gfp, reduced weight loss and viral replication and spread in the brain and to the spinal cord. Furthermore, demyelination was significantly reduced compared to that in nonrecipients. However, when P14 cells were transferred on day 3 or 5 p.i., no difference in acute or chronic disease was observed compared to that in nonrecipients. Protection in mice receiving P14 splenocytes prior to infection correlated with a robust gp33-specific immune response that was not observed in mice receiving the later transfers. Thus, an early robust CD8+ T-cell response was necessary to reduce virus replication and spread, specifically to the spinal cord, which protected against demyelination in the chronic phase of the disease.
authors.affiliation: Department of Microbiology, University of Pennsylvania, School of Medicine, 36th St. and Hamilton Walk, Philadelphia, PA 19104-6076, USA.
authors.forename: Katherine C
authors.initials: KC
authors.lastname: MacNamara
authors.forename: Ming Ming
authors.initials: MM
authors.lastname: Chua
authors.forename: Peter T
authors.initials: PT
authors.lastname: Nelson
authors.forename: Hao
authors.initials: H
authors.lastname: Shen
authors.forename: Susan R
authors.initials: SR
authors.lastname: Weiss
mesh_terms: D000818:Animals; D001921:Brain / Q000473:pathology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D017934:Coronavirus / Q000254:growth & development / Q000276:immunology*; D018352:Coronavirus Infections / Q000276:immunology* / Q000821:virology; D003711:Demyelinating Diseases / Q000517:prevention & control*; D004195:Disease Models, Animal; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013116:Spinal Cord / Q000473:pathology / Q000821:virology*; D010948:Viral Plaque Assay
chemical_list: D018984:Epitopes, T-Lymphocyte
references.citation: J Immunol. 1999 Dec 1;163(11):6106-13
references.pmid: 10570300
references.citation: J Immunol. 1999 Sep 15;163(6):3379-87
references.pmid: 10477608
references.citation: J Immunol. 2000 Aug 15;165(4):2278-86
references.pmid: 10925317
references.citation: J Virol. 2000 Sep;74(17):7903-10
references.pmid: 10933698
references.citation: Virology. 2001 Oct 25;289(2):230-8
references.pmid: 11689046
references.citation: Nat Immunol. 2002 Mar;3(3):265-71
references.pmid: 11828323
references.citation: J Neurovirol. 2002 Jun;8(3):257-64
references.pmid: 12053280
references.citation: J Immunol. 2002 Aug 1;169(3):1550-5
references.pmid: 12133983
references.citation: Virology. 2002 Sep 15;301(1):109-20
references.pmid: 12359451
references.citation: J Neurovirol. 2002 Oct;8(5):381-91
references.pmid: 12402164
references.citation: Int Immunol. 2003 Jan;15(1):119-25
references.pmid: 12502732
references.citation: J Virol. 2003 Feb;77(4):2775-8
references.pmid: 12552021
references.citation: Immunity. 2003 Apr;18(4):499-511
references.pmid: 12705853
references.citation: N Engl J Med. 2003 May 15;348(20):1967-76
references.pmid: 12690091
references.citation: Virology. 2003 Aug 1;312(2):369-80
references.pmid: 12919742
references.citation: J Virol. 2004 Feb;78(3):1150-9
references.pmid: 14722270
references.citation: Adv Immunol. 1980;30:275-331
references.pmid: 6160740
references.citation: Lab Invest. 1988 Jan;58(1):31-6
references.pmid: 2826881
references.citation: J Virol. 1989 Jul;63(7):3051-6
references.pmid: 2542613
references.citation: Virology. 1989 Jun;170(2):556-60
references.pmid: 2543129
references.citation: J Neuroimmunol. 1990 Nov;30(1):31-41
references.pmid: 2172304
references.citation: Eur J Immunol. 1991 Sep;21(9):2195-202
references.pmid: 1716213
references.citation: Virology. 1994 Apr;200(1):1-10
references.pmid: 8128613
references.citation: Adv Exp Med Biol. 1993;342:327-32
references.pmid: 7516107
references.citation: J Immunol. 1994 Jul 15;153(2):818-23
references.pmid: 7912707
references.citation: J Virol. 1995 Feb;69(2):684-94
references.pmid: 7815531
references.citation: Microb Pathog. 1995 Mar;18(3):211-21
references.pmid: 7565015
references.citation: J Neurovirol. 1996 Dec;2(6):361-76
references.pmid: 8972418
references.citation: J Neurovirol. 1997 Jun;3(3):225-8
references.pmid: 9200070
references.citation: Immunity. 1998 Feb;8(2):177-87
references.pmid: 9491999
references.citation: J Immunol. 1998 Mar 15;160(6):2896-904
references.pmid: 9510193
references.citation: J Exp Med. 1998 May 18;187(10):1575-82
references.pmid: 9584136
references.citation: Adv Exp Med Biol. 1998;440:425-30
references.pmid: 9782310
references.citation: J Immunol. 1999 Feb 1;162(3):1641-7
references.pmid: 9973424
references.citation: J Immunol. 2000 Apr 15;164(8):4080-8
references.pmid: 10754301